CGIM
ORKA

Cannon Global Investment Management’s Oruka Therapeutics ORKA Stock Holding History

Cannon Global Investment Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,000
Closed -$195K – 116
2025
Q1 		$195K Buy
+19,000
New +$237K 0.34% 60

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Cannon Global Investment Management's ORKA Position: Q2 2025 in Review

Cannon Global Investment Management sold out of Oruka Therapeutics (ORKA) in Q2 2025, closing a stake of 19,000 shares — an estimated $195K sold.

Cannon Global Investment Management first reported a position in ORKA in Q1 2025 and held it in 1 quarter. The position peaked at $195K in Q1 2025. 81 funds tracked by Wall St. Rank hold ORKA as of Q2 2025.

  • Cannon Global Investment Management reported no remaining Oruka Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cannon Global Investment Management sold 19,000 Oruka Therapeutics shares in Q2 2025, an estimated $195K.
  • Cannon Global Investment Management first reported a position in Oruka Therapeutics in Q1 2025 and held it in 1 quarter.
  • Cannon Global Investment Management's Oruka Therapeutics position peaked at $195K in Q1 2025.
  • 81 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2025.

Based on Cannon Global Investment Management's 13F filing for Q2 2025, filed 29 Jul 2025.